Two drug industry executives predict President Donald Trump will roll out proposals to tackle high drug costs within the next few weeks to months, reports Bloomberg.
Here are four things to know.
- While President Trump has been a consistent critic of the pharmaceutical industry — even saying drugmakers are "getting away with murder" — he has yet to take action on drug prices.
- HHS Secretary Tom Price, MD, has held multiple brainstorming sessions with industry stakeholders to discuss strategies for lowering drug costs, according to the report.
- Allergan CEO Brent Saunders told Bloomberg the White House is "looking for ways to increase competition but also encourage investment in [research and development]."
- Novartis CEO Joe Jimenez said drug companies have proposed numerous ideas during White House sessions, including eliminating hurdles to value-based drug pricing, according to the report. Mr. Jimenez expects Trump's proposals to "preserve the business model of how we innovate and discover and develop and launch into the U.S.," reports Bloomberg.
More articles on supply chain:
HHS estimate: Mylan overcharged Medicaid by $1.27B for EpiPens
10 most-read supply chain stories in May
Fixed-dose drug combo most cost effective treatment for hypertension, study finds